* Ventyx Biosciences Inc VTYX.OQ VTYX.O is expected
to show no
change in quarterly revenue when it reports results on May 11.
*
* Refinitiv's mean analyst estimate for Ventyx Biosciences
Inc is
for a loss of 65 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 4.8%
in the last three months.
* Wall Street's median 12-month price target for Ventyx
Biosciences Inc is $55.5, above its last closing price
of $39.14.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.67 -0.64 -0.62 Beat 2.6
Sep. 30 2022 -0.43 -0.44 -0.59 Missed -33.7
Jun. 30 2022 -0.46 -0.45 -0.39 Beat 13.3
Mar. 31 2022 -0.51 -0.52 -0.45 Beat 13.4
Dec. -0.32 -1.00 -0.36 Beat 64.1
31 2021
Sep. 30 2021 -0.36 -0.36 -3.17 Missed -780.6
This summary was machine generated May 10 at 02:03 GMT. All
figures in US dollars unless otherwise stated